Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events

BACKGROUND: Cardiovascular (CV) disease is a condition with high levels of morbidity and mortality. Canakinumab is a novel monoclonal antibody therapy that has been shown to reduce CV events but is associated with side effects and high cost. The main objective for this analysis is to determine wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Boczar, Kevin E., Beanlands, Rob, Wells, George, Coyle, Doug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123368/
https://www.ncbi.nlm.nih.gov/pubmed/35607490
http://dx.doi.org/10.1016/j.cjco.2022.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123368/
https://www.ncbi.nlm.nih.gov/pubmed/35607490
http://dx.doi.org/10.1016/j.cjco.2022.01.003

Ejemplares similares